T1	Participants 47 74	bone marrow transplantation
T2	Participants 282 315	bone marrow transplantation (BMT)
T3	Participants 521 544	patients undergoing BMT
T4	Participants 611 689	140 patients undergoing either allogeneic (n = 51) or autologous BMT (n = 89).
T5	Participants 690 767	Patients were randomized to receive (n = 70) or not receive (n = 70) oral PTX
T6	Participants 1794 1797	BMT
T7	Participants 1877 1930	mortality and morbidity prevention programs after BMT
